Current Issue : July-September Volume : 2024 Issue Number : 3 Articles : 3 Articles
Proton pump inhibitors have a short half-life and hence degrade quickly in the pH of the stomach. Therefore, developing a sustained release dosage form that can deliver a long-lasting and shield the medicine from the stomach's pH becomes crucial. Using organic solvents like ethanol and dichloromethane and polymers like Eudragit S100a and HPMC K15 in different ratios, the proton pump inhibitor microballoons were created by emulsion solvent evaporation. Following preparation, the microballoons were assessed for a number of parameters. For example, the micromeretics properties revealed that the tap density ranged from 0.803±0.36 to 0.923±0.06, the bulk density from 0.741±0.04 to 0.865±0.06, the Carr's index from 3.8±7.7 to 1.04±1.08 and the angle of repose from 14.860±0.47 to 20.250±0.71. The results of the buoyancy test indicated that the percentage was between 72.68±0.37 and 83.47±0.28, the percentage of drug entrapment was between 79.81±0.21 and 92.68±0.82, the yield percentage was between 79.20±0.28 and 89.38±0.25 and the cumulative drug release percentage was between 0.203 and 99.08%. Out of all the microballoon batches that were created, the P4 batch was determined to be the most optimal due to its optimal drug content percentage and drug release rate. The batch P4 was determined to be optimal since it exhibited the highest drug entrapment efficiency of 92.68±0.82%, the highest drug content of 94.72±0.006% and the highest sustained release action of 74.67% of drug release in a 12-hour period. The prepared microballoons were known to provide the necessary sustained release effect. The microballoons that were produced showed higuchi diffusion and zero order kinetics. It was determined to be stable since the stability analysis also revealed that there had been no appreciable alterations....
The objective of this study was to develop and assess orodispersible films as a solution to the limitations of traditional dosage forms, including deterioration caused by first liver metabolism, reduced effectiveness and lack of patient adherence. The current study involved the formulation of taste-masked lansoprazole in the form of an orodispersible film. The primary aim of this formulation was to develop an orally dissolving film of lansoprazole that effectively masks its taste, hence improving patient adherence across all age groups from adults to geriatrics. The orodispersible films were fabricated using the solvent casting technique, with pullulan serving as the film-forming agent, PEG-400 as the plasticiser, citric acid as the salivary stimulant, mannitol as the sweetening agent and mixed fruit flavour as the taste-masking agent. The preparation of lansoprazole film involved the creation of an inclusion complex with sulfobutyl-ether-β-cyclodextrin (SBEβCD) using the chilling process. The study utilized a 32 factorial design to examine the impact of two independent factors, namely the concentration of pullulan (X1) and the concentration of PEG-400 (X2), on three dependent variables: in-vitro drug release, folding endurance and disintegration time. The optimized formulation was assessed for its physical appearance, thickness, moisture content, weight uniformity, surface pH measurement and stability. The optimized batch (Y5) exhibited a drug release rate of 99.94%, a folding endurance of 72 and disintegration duration of 24 seconds. The proposed formulation was confirmed to display rapid drug release and stability using ex-vivo permeation, oral mucosa sensitivity testing, release kinetics and accelerated stability investigations. The combination of lansaprazole and Sulfobutyl-ether-β-Cyclodextrin, with its taste disguised, was effectively prepared into an orodispersible film....
To treat hyperglycemia, the counter hyperglycemic medicine metformin hydrochloride, which has a place with the biguanide family, is utilized. Hepatic gluconeogenesis is the essential instrument by which it applies its belongings. Due to its viability, metformin presents various impediments, one of which is guaranteeing that it has an extensive residency period in the stomach to accomplish consistent release. Without the microspheres coming into contact with the gastric mucosa, the objective is to plan a supported delivery conveyance strategy for metformin hydrochloride that utilizes drifting microspheres to improve how much time that the medication is held in the stomach. In the examination, drifting microspheres were produced utilizing adjusted emulsion dissolvable dissemination. Oat flour powder was used to make a characteristic polymer since it is biodegradable, biocompatible, non-harmful and modest. Various measures of oat flour powder, HPMC K4M and sodium alginate were utilized as polymers to make twelve clumps of drifting microspheres, MF1-MF12. Morphology, thickness, drug content homogeneity, lightness, enlarging file and in-vitro disintegration were evaluated for the microspheres. It was resolved that MF6 had the most positive supported discharge profile among the plans as a whole. It was noticed that the blend of Oats flour powder with HPMC K4M brought about better stomach maintenance, which thusly brought about an effective upkeep of the medication discharge. Utilizing Oats flour powder and HPMC K4M to make drifting metformin hydrochloride microspheres may further develop stomach maintenance and medicine discharge. Detailing MF6 is the best of the concentrated on bunches, demonstrating this creative conveyance instrument might expand metformin hydrochloride restorative adequacy....
Loading....